BioCentury

8:00 AM GMT, Dec 19, 2011
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Strategy

Biogen's biosimilars shot

Six months after telling investors it intended to strike a biosimilars deal that wouldn't distract it from its core business, Biogen Idec Inc. announced a JV with Samsung Group that will tap into the biotech's manufacturing prowess immediately with the option to become more involved later.

Samsung is a newcomer to biotherapeutics, but Biogen Idec liked the Korean conglomerate's determination to enter biosimilars, the resources it has committed to the effort and its track record of entering new businesses.

In March 2010, Samsung disclosed its intention to invest W2.1 trillion ($2 billion) in developing biosimilars over 10 years, with the expectation of W1.8 trillion in annual revenues by 2020.

Its first step came this February, when Samsung announced a JV with Quintiles Transnational Corp. to

Read the full 1221 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.